NORTHERN TRUST CORP - TETRAPHASE PHARMACEUTICALS I ownership

TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 94 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q1 2018. The put-call ratio across all filers is 0.42 and the average weighting 0.0%.

Quarter-by-quarter ownership
NORTHERN TRUST CORP ownership history of TETRAPHASE PHARMACEUTICALS I
ValueSharesWeighting
Q2 2019$265,000
-67.0%
552,022
-8.0%
0.00%
Q1 2019$804,000
-0.6%
599,831
-16.2%
0.00%
Q4 2018$809,000
-71.4%
715,792
-30.3%
0.00%
-100.0%
Q3 2018$2,832,000
-25.2%
1,026,332
-3.3%
0.00%0.0%
Q2 2018$3,787,000
+20.4%
1,060,816
+3.5%
0.00%0.0%
Q1 2018$3,146,000
-50.9%
1,024,701
+0.8%
0.00%
-50.0%
Q4 2017$6,403,000
-8.6%
1,016,310
-0.7%
0.00%0.0%
Q3 2017$7,004,000
+10.8%
1,023,920
+15.5%
0.00%0.0%
Q2 2017$6,323,000
-18.7%
886,765
+4.8%
0.00%0.0%
Q1 2017$7,776,000
+131.3%
846,097
+1.4%
0.00%
+100.0%
Q4 2016$3,362,000
+5.6%
834,264
+0.3%
0.00%0.0%
Q3 2016$3,185,000
+21.9%
831,594
+36.9%
0.00%0.0%
Q2 2016$2,613,000
+33.7%
607,567
+43.9%
0.00%0.0%
Q1 2016$1,954,000
-57.9%
422,152
-8.8%
0.00%
-50.0%
Q4 2015$4,644,000
+39.4%
462,980
+3.7%
0.00%
+100.0%
Q3 2015$3,332,000
-80.5%
446,675
+23.7%
0.00%
-80.0%
Q2 2015$17,124,000
+46.9%
360,968
+13.4%
0.01%
+25.0%
Q1 2015$11,659,000
+2.0%
318,212
+10.6%
0.00%
+33.3%
Q4 2014$11,428,000
+153.8%
287,782
+27.5%
0.00%
+200.0%
Q3 2014$4,502,000
+108.8%
225,660
+41.2%
0.00%0.0%
Q2 2014$2,156,000
+11.2%
159,845
-10.2%
0.00%0.0%
Q1 2014$1,938,000
-26.8%
177,984
-9.1%
0.00%0.0%
Q4 2013$2,649,000
+66.1%
195,884
+39.8%
0.00%0.0%
Q3 2013$1,595,000
+561.8%
140,141
+308.3%
0.00%
Q2 2013$241,00034,3270.00%
Other shareholders
TETRAPHASE PHARMACEUTICALS I shareholders Q1 2018
NameSharesValueWeighting ↓
Broadfin Capital, LLC 1,048,642$3,219,0000.50%
Virtus ETF Advisers LLC 130,920$402,0000.35%
683 Capital Management, LLC 600,000$1,842,0000.16%
Tekla Capital Management LLC 859,322$2,638,0000.10%
DOW CHEMICAL CO /DE/ 65,000$200,0000.07%
Alambic Investment Management, L.P. 115,834$356,0000.05%
A.R.T. Advisors, LLC 262,896$807,0000.03%
Candriam S.C.A. 520,613$1,598,0000.03%
Man Group plc 1,674,341$5,140,0000.02%
Baker Brothers Advisors 935,000$2,870,0000.02%
View complete list of TETRAPHASE PHARMACEUTICALS I shareholders